Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Can-Fite Biopharma Ltd CANF

Healthcare  —  Biotechnology
2.16 (0.01) (0.46%) as of 25 Sep
Market cap
$6.5M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Can-Fite Biopharma Ltd (CANF) Business Profile

Updated before January 2025

Company Overview

Can-Fite Biopharma Ltd. (NASDAQ: CANF) is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel. Founded in 1994, the company is dedicated to the development of innovative therapies for the treatment of cancer, inflammatory diseases, and liver-related disorders. Can-Fite leverages its proprietary platform technology to develop small molecule drugs that target specific molecular pathways associated with these diseases. The company is led by Dr. Pnina Fishman, who serves as the Chief Executive Officer and Chief Scientific Officer. Dr. Fishman is a co-founder of Can-Fite and has extensive experience in immunology and molecular biology, which has been instrumental in shaping the company’s research and development strategy.

Core Business Segments

Can-Fite Biopharma operates primarily in the biopharmaceutical sector, focusing on the development of novel therapeutic solutions. The company’s core business segments include:

1. Oncology

Can-Fite is actively developing drugs to treat various forms of cancer. Its lead product candidate in this segment is Namodenoson (CF102), which is being developed for the treatment of advanced liver cancer (hepatocellular carcinoma) and other liver-related diseases. Namodenoson is an A3 adenosine receptor (A3AR) agonist, which has shown promise in preclinical and clinical trials for its anti-cancer properties.

2. Inflammatory Diseases

The company’s flagship product in this category is Piclidenoson (CF101), an oral drug designed to treat autoimmune and inflammatory diseases such as rheumatoid arthritis and psoriasis. Piclidenoson is also an A3AR agonist and has demonstrated efficacy in reducing inflammation and modulating the immune system.

3. Liver Diseases

In addition to its oncology applications, Namodenoson is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and other liver-related conditions. The drug’s dual role in oncology and liver diseases highlights its versatility and potential market impact.

4. Ophthalmology

Can-Fite is exploring the use of its A3AR platform for the treatment of ophthalmic conditions such as glaucoma and uveitis. These efforts are still in the early stages but represent a promising avenue for future growth.

Business Model

Can-Fite’s business model revolves around the development and commercialization of proprietary drug candidates. The company generates revenue through licensing agreements, milestone payments, and royalties from its partners. Can-Fite collaborates with pharmaceutical companies and research institutions worldwide to advance its clinical programs and bring its products to market. By focusing on unmet medical needs and leveraging its proprietary A3AR technology, Can-Fite aims to create high-value therapeutics that address significant gaps in the healthcare market.

Strategic Direction

Can-Fite is committed to advancing its clinical pipeline and expanding its therapeutic portfolio. The company’s strategic priorities include:

  • Advancing Clinical Trials: Can-Fite is focused on progressing its lead drug candidates, Piclidenoson and Namodenoson, through late-stage clinical trials. The company aims to secure regulatory approvals and bring these drugs to market in the coming years.
  • Expanding Indications: Can-Fite is exploring additional indications for its existing drug candidates, such as using Namodenoson for the treatment of NASH and other liver diseases.
  • Global Partnerships: The company continues to seek strategic partnerships and licensing agreements to expand its global reach and accelerate the commercialization of its products.
  • Sustainability Goals: Can-Fite is committed to conducting its research and development activities in an environmentally responsible manner. The company aims to minimize its environmental footprint while advancing its scientific objectives.

Competitive Landscape

Can-Fite operates in a highly competitive biopharmaceutical market. Key competitors include:

  • Gilead Sciences: A leader in the development of therapies for liver diseases, including NASH and hepatitis.
  • AbbVie: A major player in the autoimmune and inflammatory disease space, with blockbuster drugs like Humira.
  • Bristol-Myers Squibb: A global biopharmaceutical company with a strong oncology portfolio.
  • Novartis: A competitor in the ophthalmology market, developing treatments for glaucoma and other eye conditions.

Despite the competition, Can-Fite differentiates itself through its proprietary A3AR technology and focus on unmet medical needs.

Risk Factors

Like any biopharmaceutical company, Can-Fite faces several risks, including:

  • Regulatory Risks: The success of Can-Fite’s drug candidates depends on obtaining regulatory approvals, which can be a lengthy and uncertain process.
  • Market Dependence: The company’s revenue is heavily reliant on the success of its lead drug candidates, Piclidenoson and Namodenoson.
  • Clinical Trial Risks: The outcome of clinical trials is uncertain, and any negative results could significantly impact the company’s prospects.
  • Supply Chain Disruptions: Can-Fite relies on third-party manufacturers and suppliers, making it vulnerable to supply chain disruptions.
  • Competitive Pressure: The biopharmaceutical market is highly competitive, and Can-Fite must continuously innovate to maintain its competitive edge.

Recent Developments

In recent months, Can-Fite has made significant progress in its clinical programs. Key developments include:

  • Phase III Trials: The company has advanced its Phase III clinical trials for Piclidenoson in the treatment of rheumatoid arthritis and psoriasis.
  • Namodenoson for NASH: Can-Fite has reported positive preclinical data for Namodenoson in the treatment of NASH, paving the way for further clinical development.
  • Licensing Agreements: The company has entered into new licensing agreements with partners in Asia and Europe, expanding its global footprint.
  • COVID-19 Impact: While the pandemic posed challenges, Can-Fite successfully adapted its operations to ensure the continuity of its clinical programs.

Investment Considerations

Strengths

  • Innovative Technology: Can-Fite’s proprietary A3AR platform offers a unique approach to treating cancer, inflammatory diseases, and liver disorders.
  • Strong Pipeline: The company has a robust pipeline of drug candidates with significant market potential.
  • Global Partnerships: Strategic collaborations enhance Can-Fite’s ability to commercialize its products and expand its market reach.

Risks

  • Clinical and Regulatory Uncertainty: The success of Can-Fite’s drug candidates is not guaranteed and depends on positive clinical trial outcomes and regulatory approvals.
  • Financial Risks: As a clinical-stage company, Can-Fite relies on external funding and may face financial challenges if it fails to secure additional capital.
  • Market Competition: The biopharmaceutical market is highly competitive, and Can-Fite must compete with established players.

Conclusion

Can-Fite Biopharma Ltd. is a promising biopharmaceutical company with a strong focus on developing innovative therapies for cancer, inflammatory diseases, and liver disorders. While the company faces challenges typical of the biopharmaceutical industry, its proprietary A3AR technology and robust clinical pipeline position it well for future growth. With strategic partnerships and a commitment to addressing unmet medical needs, Can-Fite is poised to make a significant impact in the healthcare market.